Neurelis, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2007-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.neurelis.com
A Study of Olanzapine After Intranasal and Intramuscular Administration
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- Neurelis, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT06600477
- Locations
- 🇯🇴
International Pharmaceutical Research Center (IPRC) Clinical Site, Amman, Jordan
Pharmacokinetics Study of VALTOCO® in Pediatric Subjects With Epilepsy
- First Posted Date
- 2021-10-13
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Neurelis, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05076838
- Locations
- 🇺🇸
Duke University Hospital, Durham, North Carolina, United States
🇺🇸Center for Rare Neurological Diseases, Norcross, Georgia, United States
🇺🇸Boston Children's Health Physicians, Hawthorne, New York, United States
Repeat-Dose Pharmacokinetics Study of NRL-1 in Epilepsy Subjects
- First Posted Date
- 2016-03-31
- Last Posted Date
- 2021-10-05
- Lead Sponsor
- Neurelis, Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT02724423
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Le Bonheur Children's Hospita, Memphis, Tennessee, United States
🇺🇸University of Virginia, Charlottesville, Virginia, United States
Repeat Dose Safety Study of NRL-1 in Epilepsy Subjects
- First Posted Date
- 2016-03-28
- Last Posted Date
- 2022-01-31
- Lead Sponsor
- Neurelis, Inc.
- Target Recruit Count
- 175
- Registration Number
- NCT02721069
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Clinical Trials, Inc., Little Rock, Arkansas, United States
🇺🇸New York University Comprehensive Epilepsy Center, New York, New York, United States
© Copyright 2024. All Rights Reserved by MedPath